ACOU085 waxaa la siiyay bukaankii ugu horreeyay ee qaba lumis maqal la xiriira da'da (presbycusis) ee daraasadda bukaan-socodka ee Wajiga 1b ee Jarmalka. Baaritaanka hore ee bukaanada oo u dhigma shuruudaha guud ee ka-reebista/ka-reebista ee tijaabada socota ayaa ku dhawaad dhammaatay. Marka lagu daro ujeedada mabda'a ah ee daraasadda, tijaabinta badbaadada iyo dulqaadka musharraxa daroogada ee bini'aadamka markii ugu horeysay, noocyo badan oo tijaabo maqal ah oo ujeedo iyo ujeedo ah ayaa la qabtaa si ay u taageeraan baaritaanka ka-qaybgalka bartilmaameedka.
ACOU085 waa molecule yar-yar, musharraxa daawada otoprotective kaas oo wax ka beddela bartilmaameed molecular si fiican loo qeexay oo doorbidan lagu muujiyay unugyada dareenka ee dhegta gudaha, waxa loogu yeero unugyada timaha dibadda (OHC). ACOU085 waxaa lagu gartaa hab ficil oo laba geesood ah oo gaar ah: molecule-ku waxa uu kiciyaa wanaajinta shaqada maqalka waxana uu bixiyaa ilaalinta muddada dheer ee OHC-yada kala duwan. Bishii Disembar 2021, Acousia Therapeutics waxa siisay CTA Jarmal BfArM si ay u bilawdo tijaabadeedii ugu horaysay ee Bani'aadamka Wajiga 1b ee ACOU085.
"Tallaabadan xigta ee musharraxa dawada ee Acousia ee otoprotective daroogada ACOU085 ee daraasadaha ku saabsan bukaannada la ildaran presbycusis waxay calaamad u tahay horumar muhiim ah oo ku aaddan jidkeenna ku aaddan samaynta lumis maqal cudur la daweyn karo," ayuu yiri Dr. Tim Boelke, Madaxa Fulinta iyo Madaxa Caafimaadka ee shirkadda.
"Aad ayaan ugu hanweynahay in shaqadeenna cilmi-nafsiga ah ay hadda u socoto marxaladda bukaan-socodka 6 sano ka dib markii aan bilownay barnaamijka horumarinta daroogada ee de novo oo dhamaystiran oo ku saabsan bartilmaameed cusub oo cusub," ayuu raaciyay Hubert Löwenheim, Professor iyo Guddoomiyaha Waaxda Otolaryngology-Madax & Qalliinka Qoorta ee Jaamacadda Tübingen iyo Acousia Therapeutics co-aasaasaha.
